Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 6/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 11/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728431 | 0.79 | MAP4K4 (0.34) | CLK1MAP4K4MAPK1 | |
| SCHEMBL31729167 | 0.79 | MAP4K4 (0.34) | CLK1MAP4K4MAPK1 | |
| SCHEMBL31728018 | 0.79 | CLK1 (0.36) | CLK1MAP4K4MAPK1PI4KB | |
| SCHEMBL31728332 | 0.79 | CLK1 (0.38) | CLK1MAP4K4 | |
| SCHEMBL31728133 | 0.79 | CLK1 (0.36) | CLK1MAP4K4PI4KB | |
| SCHEMBL31728591 | 0.76 | EIF2AK3 (0.39) | CLK1MAP4K4PI4KB | |
| SCHEMBL31729163 | 0.75 | CLK1 (0.37) | CLK1MAP4K4MINK1PI4KB | |
| SCHEMBL22715627 | 0.74 | ADORA2A (0.37) | CLK1MAP4K4PI4KAPI4K2BPI4K2A | |
| SCHEMBL29439817 | 0.74 | ADORA2A (0.37) | CLK1MAP4K4PI4KAPI4K2BPI4K2A | |
| SCHEMBL31728618 | 0.73 | CLK1 (0.36) | CLK1PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235874-A1 | HETEROCYCLICS AS EGFR INHIBITORS | SCHRÖDINGER, INC. (US) | 2025-11-13 | — | — | WO | disclosed |